| Revision as of 17:22, 18 April 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (← Previous edit | Revision as of 14:07, 3 September 2011 edit undoBogBot (talk | contribs)Bots53,132 edits populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBotNext edit → | ||
| Line 1: | Line 1: | ||
| {{ |
{{Drugbox | ||
| | verifiedrevid = 405764220 | | verifiedrevid = 405764220 | ||
| | IUPAC_name |
| IUPAC_name = 8-chloro-3-(methoxymethyl)-5-methyl-4H-imidazobenzodiazepin-6-one | ||
| | image |
| image = PWZ-029_structure.png | ||
| | CAS_number = | |||
| <!--Clinical data--> | |||
| ⚫ | | ATC_prefix |
||
| | |
| tradename = | ||
| | |
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | ||
| | |
| pregnancy_US = <!-- A / B / C / D / X --> | ||
| | pregnancy_category = | |||
| ⚫ | | C=14|H=14|Cl=1|N=3|O=2 | ||
| ⚫ | | legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> | ||
| ⚫ | | molecular_weight |
||
| ⚫ | | legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> | ||
| ⚫ | | smiles |
||
| ⚫ | | legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> | ||
| ⚫ | | bioavailability |
||
| ⚫ | | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> | ||
| | protein_bound = | |||
| | legal_status = | |||
| ⚫ | | metabolism |
||
| ⚫ | | routes_of_administration = | ||
| | elimination_half-life = | |||
| ⚫ | | excretion |
||
| <!--Pharmacokinetic data--> | |||
| | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | |||
| ⚫ | | bioavailability = | ||
| | pregnancy_US = <!-- A / B / C / D / X --> | |||
| | |
| protein_bound = | ||
| ⚫ | | metabolism = | ||
| ⚫ | | legal_AU |
||
| ⚫ | | excretion = | ||
| ⚫ | | legal_CA |
||
| ⚫ | | legal_UK |
||
| <!--Identifiers--> | |||
| ⚫ | | legal_US |
||
| | |
| CAS_number = | ||
| ⚫ | | ATC_prefix = | ||
| ⚫ | | routes_of_administration = | ||
| | ATC_suffix = | |||
| | PubChem = 9971547 | |||
| | DrugBank = | |||
| <!--Chemical data--> | |||
| ⚫ | | C=14 | H=14 | Cl=1 | N=3 | O=2 | ||
| ⚫ | | molecular_weight = 291.732 g/mol | ||
| ⚫ | | smiles = c3c(Cl)ccc-1c3C(=O)N(C)Cc2n-1cnc2COC | ||
| }} | }} | ||
Revision as of 14:07, 3 September 2011
Pharmaceutical compound | |
| Identifiers | |
|---|---|
IUPAC name
| |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H14ClN3O2 |
| Molar mass | 291.732 g/mol g·mol |
| 3D model (JSmol) | |
SMILES
| |
| (verify) | |
PWZ-029 is a benzodiazepine derivative drug with nootropic effects. It acts as a subtype-selective, mixed agonist-inverse agonist at the benzodiazepine binding site on the GABAA receptor, acting as a partial inverse agonist at the α5 subtype and a weak partial agonist at the α3 subtype. This gives it a mixed pharmacological profile, producing at low doses memory-enhancing effects but with no convulsant or anxiogenic effects or muscle weakness, although at higher doses it produces some sedative effects.
See also
References
- Savić MM, Clayton T, Furtmüller R, Gavrilović I, Samardzić J, Savić S, Huck S, Sieghart W, Cook JM. PWZ-029, a compound with moderate inverse agonist functional selectivity at GABA(A) receptors containing alpha5 subunits, improves passive, but not active, avoidance learning in rats. Brain Research. 2008 May 7;1208:150-9. doi:10.1016/j.brainres.2008.02.020 PMID 18394590
| Psychostimulants, agents used for ADHD, and nootropics (N06B) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| N06BA Centrally acting sympathomimetics | |||||||||
| N06BC Xanthine derivatives | |||||||||
| N06BX Other psychostimulants and nootropics | |||||||||
| |||||||||
 | This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it. |